Cannara Biotech Inc. reported earnings results for the third quarter and nine months ended May 31, 2022. For the third quarter, the company reported sales was CAD 0.827187 million compared to CAD 0.809913 million a year ago. Revenue was CAD 10.06 million compared to CAD 7.16 million a year ago. Net income was CAD 1.43 million compared to CAD 1.7 million a year ago. Basic earnings per share from continuing operations was CAD 0.1 compared to CAD 0.1 a year ago. Diluted earnings per share from continuing operations was CAD 0.1 compared to CAD 0.1 a year ago.
For the nine months, sales was CAD 2.55 million compared to CAD 2.12 million a year ago. Revenue was CAD 24.05 million compared to CAD 10.79 million a year ago. Net loss was CAD 0.248025 million compared to CAD 2.66 million a year ago. Basic loss per share from continuing operations was CAD 0.1 compared to CAD 0.1 a year ago. Diluted loss per share from continuing operations was CAD 0.1 compared to CAD 0.1 a year ago.